Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients\' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year.
Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name \"Seroquel\". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name \"Seroquel XR\", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.
In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.
The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.
On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.
On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy\'s Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.
Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name \"Seroquel\". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name \"Qi Wei\". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name \"Shu Si\". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012.
According to CRI\'s market investigation, Seroquel produced by Astra Zeneca takes up over 70% of quetiapine market in Chinese sample hospitals, followed by Qi Wei produced by Hunan Dongting Pharmaceutical Co., Ltd. and Shu Si produced by Suzhou Pharmaceutical Group Co., Ltd.
The CAGR of sales value of quetiapine surpassed 25% in Chinese sample hospitals from 2005 to 2012. Its growth rate has been declining slightly since 2010, but an annual growth rate of 10% is basically maintained. Quetiapine is now listed in Guidelines of Mental Illness Treatment in China. It is considered as a first-line drug to treat schizophrenia in Chinese market. Estimation indicates that the number of schizophrene in China will continue to rise in the next few years, leaving huge market space to grow for quetiapine.
Through this report, the readers can acquire the following information:
- Incidence of Schizophrenia in China
- Market Share of Major Quetiapine Manufacturers in China Sample Hospitals
- Sales price of Quetiapine in China Hospital Market
- Production Status of Quetiapine Generic Drug in China
- Major Quetiapine Manufacturers in China
- Prospect of China Quetiapine Market
Table of Content
1 Relevant Concepts of Quetiapine
1.2 Sales Status on the Global Market
2 Market Overview of Quetiapine in China
2.1 Patent Status
2.2 Production Status of Generic Drug
2.3 Major Manufacturers
2.4 Market Size
3 Investigation on Sales Value of Quetiapine in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Quetiapine Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Quetiapine by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Quetiapine Produced by Different Enterprises in China Hospital Market, 2014
6.1 Hunan Dongting Pharmaceutical Co., Ltd.
6.2 Suzhou Pharmaceutical Group Co., Ltd.
7 Analysis on Major Quetiapine Manufacturers in China, 2009-2014
7.1 Hunan Dongting Pharmaceutical Co., Ltd.
7.2 Suzhou Pharmaceutical Group Co., Ltd.
8 Prospect of China Quetiapine Market, 2014-2018
8.1 Prediction of Schizophrenia Incidence in China
8.2 Research Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Market Competition
List of Chart
Chart Quetiapine Products Approved to Market in China by 2014
Chart Sales Value of Quetiapine in Global Market, 2009-2013
Chart Sales Value of Quetiapine in China Sample Hospital Market, 2009-2013
Chart Sales Value of Quetiapine by Region in China, 2009-2013
Chart Market Share of Quetiapine Enterprises by Sales Volume in China, 2009-2013
Chart Price of Quetiapine Produced by MSD (UK) in China Hospital Market, 2013
Chart Price of Quetiapine Produced by Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd. in China Hospital Market, 2013
Chart Forecast on Market Size of Hospital-use Quetiapine in China, 2014-2018
Chart Sales Value of Singulair in Global Market, 2008-2013
Make an enquiry before buying this Report
Please fill the enquiry form below.